Seattle-based Tasso designed its device for single-use, patient-centric blood collection. It provides a simple, virtually painless blood collection experience.
The company said in a news release that Tasso+ is the first device of its kind to receive Class II FDA clearance as part of a new reclassification process. The classification covers lancets intended to puncture the skin to obtain drops of capillary blood samples.
It all comes as part of the FDA’s effort to ensure the safe and effective use of lancets in the home and healthcare settings. Tasso said clearance allows pharmaceutical companies to accelerate decentralized clinical trials. Additionally, healthcare systems and physicians can use Tasso+ with compatible collection tubes to make determinations on blood chemistries.
Tasso intends to make the solutions …